SEC Form 4 · accession 0001140361-17-018553
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Pendarvis
Officer — Chief Administrative Officer
Period of report
May 3, 2017
Accepted (ET)
May 5, 2017 · 11:58 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | May 3, 2017 | M | 6,365 | $27.58 | A | 84,261 | D | |
| ResMed Common StockF2 | May 3, 2017 | S | 6,365 | $69.549 | D | 77,896 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock OptionsF3 | $27.58 | May 3, 2017 | M | 6,365 | D | Nov 11, 2012 | Nov 16, 2018 | ResMed Common Stock | 6,365 | 38,185 | D |
Explanation of responses
- F1The transaction was conducted under a Rule 10b5-1 plan.
- F2This transaction was executed in multiple trades at prices ranging from $69.45 to $69.63. The price reported above reflects the weighted average sale price.
- F3Represents date options first became exercisable. Options vest 1/4 per year.